Roche Holding AG is a Switzerland-based healthcare company that develops and supplies pharmaceutical products and diagnostic systems. Its business is organized around two primary divisions: Pharmaceuticals, which focuses on medicines for areas such as oncology, immunology, neuroscience, ophthalmology and rare diseases; and Diagnostics, which provides laboratory tests, instruments and digital solutions used for disease detection, monitoring and treatment decisions.
The company markets prescription medicines under brands that include Ocrevus, Hemlibra, Vabysmo, Tecentriq and Alecensa, as well as a broad portfolio of in-vitro diagnostic products and services. Roche also conducts research in personalized healthcare, combining diagnostic information with targeted therapies to support more individualized patient treatment.
Founded in 1896 and headquartered in Basel, Switzerland, Roche serves healthcare providers, laboratories and patients internationally through operations and distribution networks spanning numerous regions, including Europe, North America and Asia-Pacific. The company has maintained a close relationship with Genentech, its U.S.-based biotechnology subsidiary, which Roche acquired in 2009.
Roche is led by Chief Executive Officer Thomas Schinecker, who assumed the role in 2023, and Chairman Severin Schwan. The company’s shares trade on the SIX Swiss Exchange, with additional over-the-counter trading in the United States under the symbol RHHVF.
AI Generated. May Contain Errors.